Candida albicans is a diploid fungus (a form of yeast), which is capable of sexual reproduction but not of meiosis, and a causal agent of opportunistic oral and genital infections in humans.[3][4] Systemic fungal infections (fungemias) have emerged as important causes of morbidity and mortality in immunocompromised patients (e.g., AIDS, cancer chemotherapy, organ or bone marrow transplantation). In addition, hospital-related infections in patients not previously considered at risk (e.g. patients in an intensive care unit) have become a cause of major health concern.

C. albicans is commensal and is among the gut flora, the many organisms which live in the human mouth and gastrointestinal tract. Under normal circumstances, C. albicans lives in 80% of the human population with no harmful effects, although overgrowth results in candidiasis. Candidiasis is often observed in immunocompromised individuals such as HIV-positive patients. Candidiasis also may occur in the blood and in the genital tract. Candidiasis, also known as “thrush”, is a common condition which is usually easily cured in people who are not immunocompromised. To infect host tissue, the usual unicellular yeast-like form of C. albicans reacts to environmental cues and switches into an invasive, multicellular filamentous forms.[3]


One of the most interesting features of the C. albicans genome is the occurrence of numeric and structural chromosomal rearrangements as means of generating genetic diversity, named chromosome length polymorphisms (contraction/expansion of repeats), reciprocal translocations, chromosome deletions and trisomy of individual chromosomes. These karyotypic alterations lead to changes in the phenotype, which is an adaptation strategy of this fungus. These mechanisms will be better understood with the complete analysis of the C. albicans genome.

The C. albicans genome for strain SC5314 was sequenced at the Stanford DNA Sequencing and Technology Center.[5][6] The genome of the WO1 strain was sequenced by the Broad Institute of MIT and Harvard.[7]

The sequencing of the C. albicans genome and subsequently of the genomes of several other medically relevant Candida species has profoundly and irreversibly changed the way Candida[4] The C. albicans genome sequencing effort was launched in October 1996. Successive releases of the sequencing data and genome assemblies have marked the last 10 years, culminating with the release of the diploid assembly 19 which provided a haploid version of the genome along with data on allelic regions in the genome.[4] A refined assembly 20 with the eight assembled C. albicans chromosomes was released in the summer of 2006. Importantly, the availability of sequencing data prior to the completion of the genome sequence has made it possible to start C. albicans post-genomics early on. In this regard, genome databases have been made available to the research community providing different forms of genome annotation. These have been merged in a community-based annotation hosted by the Candida Genome Database. The availability of the genome sequence has paved the way for the implementation of post-genomic approaches to the study of C. albicans: macroarrays and then microarrays have been developed and used to study the C. albicansC. albicans gene in different contexts. Other Candida genome sequences have been, or are being, determined: C. glabrata, C. dubliniensis, C. parapsilosis, C. guilliermondii, C. lusitaniae, and C. tropicalis. These species will soon enter the post-genomic era as well and provide interesting comparative data. The genome sequences obtained for the different Candida species along with those of non-pathogenic hemiascomycetes provide a wealth of knowledge on the evolutionary processes which have shaped the hemiascomycete group as well as those which may have contributed to the success of different Candida species as pathogens.[4] species are now investigated and understood. transcriptome; proteomics has also been developed and complements transcriptional analyses; furthermore, systematic approaches are becoming available to study the contribution of each

The genome of C. albicans is highly dynamic and this variability has been used advantageously for molecular epidemiological studies of C. albicans and population studies in this species. A remarkable discovery which has arisen from the genome sequence is the presence of a parasexual cycle in C. albicans. This parasexual cycle is under the control of mating-type loci and switching between white and opaque phenotypes. Investigating the role which the mating process plays in the dynamics of the C. albicans population or in other aspects of C. albicans biology and pathogenicity will undoubtedly represent an important focus for future research.[4]


In a process which superficially resembles dimorphism, C. albicans undergoes a process called phenotypic switching, in which different cellular morphologies are generated spontaneously. One of the classically studied strains which undergoes phenotypic switching is WO-1[8], which consists of two phases – one which grows as smooth white colonies and one which is rod-like and grows as flat gray colonies. The other strain known to undergo switching is 3153A; this strain produces at least seven different colony morphologies. In both the WO-1 and 3153A strains, the different phases convert spontaneously to the other(s) at a low frequency. The switching is reversible, and colony type can be inherited from one generation to another. While several genes which are expressed differently in different colony morphologies have been identified, some recent efforts have focused on what might be controlling these changes. Further, whether there is a potential molecular link between dimorphism and phenotypic switching is a tantalizing question.

In the 3153A strain, a gene called SIR2 (for silent information regulator) has been found which seems to be important for phenotypic switching. SIR2 was originally found in Saccharomyces cerevisiae (brewer’s yeast), where it is involved in chromosomal silencing — a form of transcriptional regulation in which regions of the genome are reversibly inactivated by changes in chromatin structure (chromatin is the complex of DNA and proteins which make chromosomes). In yeast, genes involved in the control of mating type are found in these silent regions, and SIR2 represses their expression by maintaining a silent-competent chromatin structure in this region. The discovery of a C. albicans SIR2 which is implicated in phenotypic switching suggests that it too has silent regions controlled by SIR2, in which the phenotype-specific genes may perhaps reside.

Another potential regulatory molecule is Efg1p, a transcription factor found in the WO-1 strain which regulates dimorphism, and more recently has been suggested to help regulate phenotypic switching. Efg1p is expressed only in the white and not in the gray cell-type, and overexpression of Efg1p in the gray form causes a rapid conversion to the white form.[9][10]

So far there are few data which say that dimorphism and phenotypic switching use common molecular components. However, it is not inconceivable that phenotypic switching may occur in response to some change in the environment as well as being a spontaneous event. How SIR2 itself is regulated in S. cerevisiae may yet provide clues as to the switching mechanisms of C. albicans.


The heterozygosity of the Candida genome exceeds that found in other genomes and is widespread among clinical isolates. Non-synonymous single base polymorphisms result in two proteins that differ in one or several amino acids that may confer functional differences for each protein. This situation considerably increases the number of different proteins encoded by the genome.[11]

Homeopathy Treatment for Candida albicans

Keywords: homeopathy, homeopathic, treatment, cure, remedy, remedies, medicine

Homeopathy treats the person as a whole. It means that homeopathic treatment focuses on the patient as a person, as well as his pathological condition. The homeopathic medicines are selected after a full individualizing examination and case-analysis, which includes the medical history of the patient, physical and mental constitution, family history, presenting symptoms, underlying pathology, possible causative factors etc. A miasmatic tendency (predisposition/susceptibility) is also often taken into account for the treatment of chronic conditions. A homeopathy doctor tries to treat more than just the presenting symptoms. The focus is usually on what caused the disease condition? Why ‘this patient’ is sick ‘this way’. The disease diagnosis is important but in homeopathy, the cause of disease is not just probed to the level of bacteria and viruses. Other factors like mental, emotional and physical stress that could predispose a person to illness are also looked for. No a days, even modern medicine also considers a large number of diseases as psychosomatic. The correct homeopathy remedy tries to correct this disease predisposition. The focus is not on curing the disease but to cure the person who is sick, to restore the health. If a disease pathology is not very advanced, homeopathy remedies do give a hope for cure but even in incurable cases, the quality of life can be greatly improved with homeopathic medicines.

The homeopathic remedies (medicines) given below indicate the therapeutic affinity but this is not a complete and definite guide to the homeopathy treatment of this condition. The symptoms listed against each homeopathic remedy may not be directly related to this disease because in homeopathy general symptoms and constitutional indications are also taken into account for selecting a remedy. To study any of the following remedies in more detail, please visit the Materia Medica section at Hpathy.

None of these medicines should be taken without professional advice and guidance.

Homeopathy Remedies for Candida albicans :

Calc., calc-p., chin., helon., lyc., med., nat-p., nit-ac., puls., sep., thuj.

{googleAds}{include_content_item 462}{/googleAds}


  1. ^ Candida albicans at NCBI Taxonomy browser, url accessed 2006-12-26
  2. ^ “Factors Affecting the Morphology of Candida Albicans” Dan Otho McClary Annals of the Missouri Botanical Garden, Vol. 39, No. 2 (May, 1952), pp. 137-164. doi:10.2307/2394509
  3. ^ a b Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. ISBN 0-8385-8529-9.
  4. ^ a b c d e dEnfert C; Hube B (editors) (2007). Candida: Comparative and Functional Genomics. Caister Academic Press. ISBN 9781904455134.
  5. ^ Jones T, Federspiel NA, Chibana H, et al (May 2004). “The diploid genome sequence of Candida albicans”. Proceedings of the National Academy of Sciences of the United States of America 101 (19): 7329–34. doi:10.1073/pnas.0401648101. PMID 15123810. PMC: 409918.
  6. ^ Braun BR, van Het Hoog M, d’Enfert C, et al (July 2005). “A human-curated annotation of the Candida albicans genome”. PLoS genetics 1 (1): 36–57. doi:10.1371/journal.pgen.0010001. PMID 16103911. PMC: 1183520.
  7. ^ “Candida Database”. Broad Institute. 2008-10-29. Retrieved on 2008-11-02.
  8. ^ Rikkerrink E, Magee B, Magee P (1988). “Opque-white phenotype transition: a programmed morphological transition in Candida albicans”. J. Bact. 170 (2): 895–899.
  9. ^ Sonneborn A, Tebarth B, Ernst J (1999). “Control of white-opaque phenotypic switching in Candida albicans by the Efg1p morphogenetic regulator”. Infect. Immu. 67 (9): 4655–4660.
  10. ^ Srikantha T, Tsai L, Daniels K, Soll D (2000). “EFG1 null mutants of Candida albicans switch but cannot express the complete phenotype of white-phase budding cells”. J. Bact. 182 (6): 1580–1591. doi:10.1128/JB.182.6.1580-1591.2000. PMID 10692363.
  11. ^ Larriba G; Calderone RA (2008). “Heterozygosity and Loss of Heterozygosity in Candida albicans”. Pathogenic Fungi: Insights in Molecular Biology. Caister Academic Press. ISBN 978-1-904455-32-5.